Favrille Sets IPO Pricing Range

San Diego-based biotech firm Favrille set the range for its IPO Friday, saying that it will offer up to 6.9M shares of its stock at $12.00 to $14.00 per share. The company is developing patient-specific therapeutics for lymphoma and diseases of the immune system. The company has applied to list its stock on the Nasdaq as FVRL. The company's IPO is being underwritten by Bear Stearns & Co., CIBC World Markets, Needham & Company, and AG Edwards.